Humira Replaces Enbrel as the Therapy Perceived by Dermatologists to be the Most Efficacious for the Treatment of Moderate to Severe Psoriasis

Tuesday, March 23, 2010 General News
Email Print This Page Comment bookmark
Font : A-A+

Stelara Will Retain Decision Resources' Clinical Gold-Standard Status Through 2018 for Moderate to Severe Psoriasis, According to a New Report from Decision Resources

For more information, contact:

Decision Resources

Decision Resources, Inc.

Lisa Osgood

Christopher Comfort

781-296-2606

781-296-2597

[email protected]

[email protected]



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook